Results 151 to 160 of about 265,755 (306)

Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Most antiseizure medications (ASMs) are prescribed off label for neonates. Lacosamide's efficacy in infants and availability in intravenous formulation suggest potential utility for neonates. We evaluated the safety and efficacy of lacosamide for neonatal seizures. Methods This 10‐center, retrospective study of neonates with seizures
Alexandra Santana Almansa, Jessica R. Landers, Nicholas S. Abend, Giulia M. Benedetti, Catherine J. Chu, Andrew T. Knox, Shavonne Massey, Steffany Moen, Andrea C. Pardo, Arnold Sansevere, Renée A. Shellhaas, Cameron Thomas, Tammy Tsuchida, Sonya Wang, Bo Zhang, Janet S. Soul   +15 more
wiley   +1 more source

Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Mocravimod, a novel immunomodulator targeting sphingosine‐1‐phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism.
Dymphy R. Huntjens, Stephan Oehen, Elisabeth Kueenburg   +2 more
wiley   +1 more source

Major Adverse Cardiac Events with Ondansetron: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence base: 170 randomized trials, 23,421 adults, predominantly single‐dose IV ondansetron, mean follow‐up 20 days. Observed outcomes: Major adverse cardiac events were rare, no ventricular arrhythmias or torsades de pointes observed. Conclusion: Ondansetron was not associated with increased mortality or serious cardiac arrhythmias in adult ...
Michael Cristian Garcia, Bhavya Gandhi, Faisal Quadri, Mahnoor Shahab, Kassie Rong, Genevieve Ramnarine, Ishleen Sudan, Sophia Zhang, Michelle Yu, Sara Mojdehi, Lawrence Mbuagbaw, Anne M. Holbrook   +11 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray, Claire McNamara, Anna V. Chatzi   +2 more
wiley   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai, Minoru Yasukawa, Shigeru Shibata   +2 more
wiley   +1 more source

Hypoglycaemia and Cardiac Arrhythmias in Type 1 Diabetes Mellitus: A Mechanistic Review. [PDF]

J Pers Med
Mavromoustakou K, Fragoulis C, Cholidou K, Sotiropoulou Z, Anagnostopoulos N, Gastouniotis I, Lontou SP, Dimitriadis K, Thanopoulou A, Chrysohoou C, Tsioufis K.   +10 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Arrhythmias across the tree of life: comparative insights for human electrophysiology. [PDF]

Front Cardiovasc Med
Natterson-Horowitz B, Wright K, Van Steenkiste G, Decloedt A, Gagnon AL, Cai X, Mazmanian A.   +6 more
europepmc   +1 more source